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NF-B transcription factors, which are com-
posed of dimers of Rel polypeptides, regulate 
gene expression by binding to B elements in 
the promoters and enhancers of target genes 
(Ghosh et al., 1998). Inactive NF-B dimers are 
sequestered in the cytoplasm of unstimulated 
cells by interaction with proteins of the inhibi-
tor of NF-B (IB) family, which includes 
IBa, IBb, IBe, and NF-B2 p100. After 
appropriate agonist stimulation, the canonical 
NF-B signaling pathway stimulates the IB ki-
nase (IKK) complex, which is composed of IKK1 
(IKKa) and IKK2 (IKKb) kinases and the 
regulatory ubiquitin-binding protein NEMO 
(IKKg), to phosphorylate IBa (Karin and Ben-
Neriah, 2000). This promotes K48-linked ubiq-
uitination of IBa and subsequent degradation 
by the proteasome, releasing associated NF-B1 
p50-RelA and NF-B1 p50-c-Rel dimers to 
translocate into the nucleus and modulate gene 
expression. The proteolysis of both IBb and 
IBe is controlled by the IKK complex in a 
similar fashion. A subset of NF-B agonists ac-
tivates an alternative NF-B signaling pathway, 
which induces IKK1 to phosphorylate NF-B2 
p100 promoting its partial proteolysis by the 
proteasome to produce p52, which is principally 
associated with RelB (Beinke and Ley, 2004).
Most of our knowledge about the specific 
functions of NF-B activation in mature B cells 
is based on in vitro experiments with purified 
splenic B cells from mice deficient in specific 
Rel proteins (Kaileh and Sen, 2012). These 
studies have suggested important roles for ca-
nonical NF-B activation in B cell growth, 
proliferation, and survival after B cell antigen 
receptor (BCR) stimulation (Grumont et al., 
1999; Grumont et al., 1998, 2002). Whole animal 
studies have also demonstrated a requirement 
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The importance of IB kinase (IKK)–induced proteolysis of NF-B1 p105 in B cells was 
investigated using Nfkb1SSAA/SSAA mice, in which this NF-B signaling pathway is blocked. 
Nfkb1SSAA mutation had no effect on the development and homeostasis of follicular mature 
(FM) B cells. However, analysis of mixed bone marrow chimeras revealed that Nfkb1SSAA/SSAA 
FM B cells were completely unable to mediate T cell–dependent antibody responses. 
Nfkb1SSAA mutation decreased B cell antigen receptor (BCR) activation of NF-B in FM  
B cells, which selectively blocked BCR stimulation of cell survival and antigen-induced differ-
entiation into plasmablasts and germinal center B cells due to reduced expression of Bcl-2 
family proteins and IRF4, respectively. In contrast, the antigen-presenting function of FM  
B cells and their BCR-induced migration to the follicle T cell zone border, as well as their 
growth and proliferation after BCR stimulation, were not affected. All of the inhibitory 
effects of Nfkb1SSAA mutation on B cell functions were rescued by normalizing NF-B 
activation genetically. Our study identifies critical B cell-intrinsic functions for IKK-induced 
NF-B1 p105 proteolysis in the antigen-induced survival and differentiation of FM B cells, 
which are essential for T-dependent antibody responses.
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IKK-induced proteolysis of NF-B1 p105 in regulating the de-
velopment and function of B cells, via NF-B and/or TPL-2, 
remain unknown.
In the present study, the effect of blocking IKK phosphoryla-
tion of NF-B1 p105 in B cells was investigated using Nfkb1SSAA/
SSAA knock-in mice, which express mutant p105SSAA that is resis-
tant to signal-induced proteolysis due to mutation of the 
IKK2-target serines to alanines (Sriskantharajah et al., 2009). 
We found that Nfkb1SSAA mutation had no effect on B cell 
development in the BM, or on the number of follicular ma-
ture (FM) B cells in the spleen or LNs. However, analysis of 
mixed BM chimeras in which the Nfkb1SSAA mutation was 
restricted to B cells revealed that Nfkb1SSAA FM B cells were 
completely unable to mount an immune response to a T cell–
dependent (TD) antigen, failing to develop into antigen-specific 
plasmablasts or germinal center (GC) B cells. In contrast, TPL-2 
deficiency in FM B cells did not affect a TD antibody re-
sponse. The Nfkb1SSAA mutation was found to decrease BCR 
activation of NF-B in FM B cells, which prevented BCR 
signaling promoting cell survival, but had minimal inhibitory 
effects on BCR-induced growth and proliferation. Signifi-
cantly, we also discovered that Nfkb1SSAA mutation reduced 
NF-B–dependent induction of the IRF4 transcription fac-
tor after BCR ligation, which prevented antigen-induced dif-
ferentiation of FM B cell to plasmablasts and GC B cells. All of 
the inhibitory effects of Nfkb1SSAA mutation on FM B cell func-
tion were overcome by normalizing NF-B activation geneti-
cally. Our results demonstrate that the regulation of NF-B 
activation in B cells by IKK-induced proteolysis of NF-B1 
p105 is essential for antibody responses to TD antigens.
RESULTS
Nfkb1SSAA mutation does not affect steady-state  
numbers of mature follicular B cells
To investigate the role of IKK-induced p105 proteolysis in 
B cell development and homeostasis, we analyzed B cell sub-
populations in the BM, secondary lymphoid organs (spleen 
and lymph nodes), and peritoneal cavity of Nfkb1SSAA/SSAA 
(Nfkb1SSAA) and WT mice by flow cytometry. B cell develop-
ment in the BM was similar between both genotypes, with simi-
lar proportions and absolute numbers of pro–B cells, pre–B cells, 
and immature B cells (Fig. 1 A and Fig. S1 A). The numbers 
of mature recirculating B cells in the BM were also unaffected 
by Nfkb1SSAA mutation. Total numbers and proportions of 
B cells in spleen and peripheral lymph nodes, respectively, were 
equivalent in Nfkb1SSAA/SSAA and WT mice (Fig. 1, B and C; 
and Fig. S1, B and C). Numbers of splenic FM B cells were 
also similar. In contrast, marginal zone (MZ) B cells number in 
the spleen were substantially reduced by Nfkb1SSAA mutation, 
whereas the numbers of transitional type 1 (T1) and type 2 
(T2) B cells were fractionally increased (Fig. 1 B). The pro-
portion of B1a cells in the peritoneal cavity was also signifi-
cantly reduced in Nfkb1SSAA/SSAA mice compared with WT 
(Fig. 1 D and Fig. S1 D). However, the fractions of peritoneal 
B1b and B2 cells were similar between genotypes.
for NF-B family members in the B cell response to antigen. 
For example, NF-B1 or c-Rel deficiency diminishes the anti-
body response, whereas compound NF-B1 and c-Rel defi-
ciency results in a complete block (Pohl et al., 2002). However, 
because both NF-B1 and c-Rel have essential roles in den-
dritic cells and T cells (Gerondakis and Siebenlist, 2010a), it 
has remained unclear whether NF-B activation in B cells is 
required for optimal antibody responses.
The cell-intrinsic functions of canonical NF-B activation 
in B cell physiology in vivo have been investigated genetically 
by conditional deletion of components of the IKK complex in 
the B cell lineage, using a CD19-Cre driver mouse strain. 
Although ablation of either IKK2 or NEMO does not affect 
B cell development in the BM, it does lead to the disappearance 
of mature B lymphocytes (Pasparakis et al., 2002; Li et al., 
2003). In line with this, mature B cells fail to accumulate in 
the periphery in the combined absence of c-Rel and RelA 
(Grossmann et al., 2000). Similarly, mice with mutations in 
components of the alternative NF-B signaling pathway, which 
regulates NF-B2 p100 proteolysis to p52, are also deficient in 
mature B cells, whereas B cell development in the BM is largely 
unaffected (Gerondakis and Siebenlist, 2010b; Kaileh and Sen, 
2012). The alternative pathway is activated downstream of the 
receptor for B cell activation factor (BAFF), which promotes 
peripheral B cells survival and determines the size of the B cell 
compartment (Mackay et al., 2010), and CD40 (Kaileh and 
Sen, 2012). Together these genetic studies have established that 
NF-B activation has a critical role for the development and/or 
homeostasis of mature B cells. However, the requirement for 
NF-B activation to maintain normal mature B cell numbers 
has precluded the use of conditional knockout strains lacking 
IKK subunits in B cells to determine the B cell–intrinsic func-
tion of NF-B activation in humoral immunity (Pasparakis 
et al., 2002; Li et al., 2003; Derudder et al., 2009).
NF-B1 p105 functions as a cytoplasmic IB through 
binding to preformed NF-B dimers via its C-terminal an-
kyrin repeat region, and to Rel monomers via its N-terminal 
Rel homology domain (Savinova et al., 2009). NF-B1 p105 
is also the precursor of p50, which is produced constitutively 
by partial proteolysis (processing) of p105 by the proteasome 
after its monoubiquitination on multiple lysine residues by an 
unknown E3 ligase (Kravtsova-Ivantsiv et al., 2009). Activa-
tion of the canonical NF-B pathway induces IKK2 to phos-
phorylate two serines in the C-terminal PEST region of p105 
(Lang et al., 2003; Yang et al., 2012), creating a binding site 
for SCFb-TrCP E3 ligase, which catalyzes the subsequent 
K48-linked polyubiquitination of p105 and proteolysis by 
the proteasome. This can result either in the complete degra-
dation of p105, releasing associated Rel subunits, or the pro-
cessing of p105 to p50, both of which can potentially modulate 
NF-B–dependent transcription (Sriskantharajah et al., 2009; 
Yang et al., 2012). In addition, IKK-induced p105 proteoly-
sis is an essential step in the activation of the p105-associated 
MEK1/2 kinase TPL-2, which regulates ERK-1/2 MAP ki-
nase activation in TLR-stimulated macrophages (Beinke et al., 
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B cells resulted from a B cell–autonomous effect of the 
Nfkb1SSAA mutation and confirmed that Nfkb1SSAA mutation 
did not affect FM B cell numbers (Fig. 1 E).
Nfkb1SSAA/SSAA B cells cannot mount  
an antibody response to a TD antigen
Measurement of steady-state levels of Ig in serum revealed 
significantly reduced IgM (Fig. 1 F), consistent with the 
reduction in MZ B cells in the spleen and B1a cells in the 
In summary, mutation of the IKK target serines on NF-B1 
p105 did not alter the overall number of peripheral mature 
B cells, in marked contrast to deletion of IKK2 or NEMO in 
the B cell lineage that results in substantially reduced numbers 
of such cells (Pasparakis et al., 2002). However, MZ B cell num-
bers were significantly reduced by Nfkb1SSAA mutation, in line 
with the known importance of NF-B for the production of 
this subset of B cells in the spleen (Pillai and Cariappa, 2009). 
Mixed BM chimeras demonstrated that the reduction in MZ 
Figure 1. Nfkb1SSAA/SSAA mice have normal numbers of FM B cells. (A–D) Flow cytometric analysis of B cell populations in WT and Nfkb1SSAA/SSAA 
mice from the indicated organs. The gating strategies used are shown in Fig. S1. (A) Absolute cell numbers of pro–B (B220+CD19+IgDIgMCD2), pre–B 
(B220+CD19+IgDIgMCD2+), immature mature B (B220+CD19+IgDIgM+CD2+), and mature B cells (B220+CD19+IgD+IgM+CD2+) in the BM (mean ± SEM; 
n = 10–11 mice/genotype). (B) Absolute cell numbers (mean ± SEM; n = 10–11 mice/genotype) of total B cells (IgM+IgD+), immature B cells (IgDloB220+AA4.1+) 
separated into transitional T1 B cells (IgMhiCD23), and T2 B cells (IgMhiCD23+), and mature B cells (IgDhiB220+AA4.1) separated into FM B cells  
(IgMhiCD23+) and MZ B cells (IgMhiCD23) in the spleen. (C) Percentages of B cells (IgM+CD19+) in peripheral lymph nodes (pools of single cervical, axil-
lary and inguinal nodes; mean ± SEM; n = 10–11 mice/genotype). (D) Proportion of B1a (B220+CD19+CD5+CD23), B1b (B220+CD19+CD5CD23), and  
B2 (B220+CD19+CD5CD23+) cells in the peritoneal cavity (mean ± SEM; n = 5–7 mice/genotype). In A–D, results are representative of at least three 
independent experiments. (E) WT or Nfkb1SSAA/SSAA CD45.2+ BM cells were mixed with WT CD45.1+ BM cells at a 1:1 ratio, and transferred into sublethally 
irradiated Rag1/ mice. After 8-wk reconstitution, the absolute number of CD45.2+ MZ B cells was assessed by flow cytometry. FM B cells were used as 
the control population. Graphs show absolute cell numbers (mean ± SEM; n = 14 mice/genotype), results are representative of two independent experi-
ments. (F) Graphs show ELISAs for IgM, IgA, IgG1, and IgG2b, assaying sera from naive WT and Nfkb1SSAA/SSAA mice. n = 18 mice per genotype. PEC,  
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MZ B cells in Nfkb1SSAA/SSAA mice, therefore, should not 
contribute significantly to TD antibody responses, although 
this might decrease antibody responses to T cell–independent 
antigens. Consequently, any detected effects of Nfkb1SSAA 
mutation on antibody responses to a TD antigen were likely 
to result from alterations in the function of FM B cells (Oracki 
et al., 2010), as their numbers were normal in Nfkb1SSAA/SSAA 
mice (Fig. 1 B).
To investigate the B cell–intrinsic effects of Nfkb1SSAA mu-
tation on FM B cell function, we generated mixed BM chime-
ras. BM cells from mMT/ mice, lacking B cells (Kitamura 
peritoneum (Zhang, 2013). Serum titers of IgA and both 
IgG1 and IgG2b were also significantly decreased in unimmu-
nized mice, raising the possibility that one or several aspects of 
antibody responses might also be impaired by Nfkb1SSAA mu-
tation. Because we were interested in investigating the role of 
NF-B1 p105 proteolysis in B cell function in immunity, we 
focused our subsequent experiments on the effects of Nfkb1SSAA 
mutation on TD antibody responses. It has previously been 
shown that RBP-J–deficient mice, which lack MZ B cells, are 
still able to generate normal antibody responses to chicken 
gammaglobulin (CGG; Tanigaki et al., 2002). The reduction in 
Figure 2. Nfkb1SSAA/SSAA mutation blocks the B cell antibody response to a TD antigen. WT or Nfkb1SSAA/SSAA BM cells were mixed with mMT/ 
BM cells in a 1:4 ratio, and transferred into sublethally irradiated Rag1/ mice. After 8 wk, chimeras were immunized with NP27-CGG alum or PBS alum 
controls. (A) Serum antibody response to NP27-CGG immunization of WT or Nfkb1SSAA/SSAA mixed BM chimeras assessed 7 and 14 d after challenge.  
Data show mean NP-specific serum IgM and IgG1 levels (±SEM) measured by ELISA. (B) Flow cytometric analysis of total naive B cells (IgM+B220+; left) 
and aNP-IgG1+ plasmablasts (PB; B220loIgMloIgDCD138+; right) in the spleens of chimeras 7 d after NP27-CGG immunization (mean absolute number ± 
SEM). (C) Flow cytometric analysis of total GC B cells (IgMloB220+IgDPNAhiGL7+; left) and aNP-IgG1+ GC B cells (right) in chimeras 14 d after 
NP27-CGG immunization (mean absolute number ± SEM). (D) Confocal microscopy of spleen sections from WT or Nfkb1SSAA/SSAA chimeras immunized with 
NP27-CGG (14d). GC formation was measured by staining with anti-IgD (red), anti-B220 (blue) and GL7 (green). In A–D, results are representative of at 
least three independent experiments with n = 5 mice per genotype. (E) WT or Nfkb1SSAA/SSAA CD45.2+ BM cells were mixed with WT CD45.1+ and mMT/ 
BM cells in a 1:1:3 ratio, and transferred into sublethally irradiated Rag1/ mice. After an 8-wk reconstitution, chimeras were immunized with NP27-CGG 
alum or alum alone. Graph shows the flow cytometric analysis of aNP+ IgG1+ plasmablasts (PB), 7 and 14 d after NP27-CGG immunization. Results are 
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suggested that the failure of Nfkb1SSAA/SSAA FM B cells to 
mount an antibody response to NP27-CGG did not result 
from defective TPL-2 signaling, and was likely due to altered 
NF-B activation.
To investigate this possibility, we determined the effect of 
Nfkb1SSAA mutation on NF-B activation in purified splenic 
FM B cells in vitro. Steady-state protein levels of RelA, RelB, 
and c-Rel were comparable between Nfkb1SSAA/SSAA and WT 
FM B cells (Fig. 4 A). However, similar to our previous find-
ings with macrophages (Yang et al., 2012), Nfkb1SSAA muta-
tion increased the steady-state concentration of NF-B1 p105, 
while NF-B1 p50 was reduced. Nfkb1 mRNA levels were 
comparable between Nfkb1SSAA/SSAA and WT FM B cells (un-
published data), implying that these changes in p105 and p50 
protein levels resulted from Nfkb1SSAA mutation blocking 
constitutive p105 phosphorylation by IKK. Consistent with 
that hypothesis, unstimulated WT FM B cells had small 
amounts of phosphorylated p105, that increased after stimula-
tion with anti-IgM, CD40L and LPS (Fig. 4 B and not de-
picted). In addition, steady-state levels of NF-B2 p52 were 
increased in Nfkb1SSAA/SSAA B cells compared with WT, 
whereas levels of p100 were fractionally reduced (Fig. 4 A), 
suggesting that Nfkb1SSAA mutation increased constitutive 
activation of the NF-B alternative pathway.
Nuclear translocations of RelA and p50, after stimulation 
with anti-IgM for 1 h, were clearly decreased in Nfkb1SSAA/SSAA 
FM B cells compared with WT cells (Fig. 4 C). Accordingly, 
NF-B ELISAs demonstrated that Nfkb1SSAA mutation im-
paired BCR activation of p50 and RelA binding activity at 1 h 
(Fig. 4 D). Although nuclear translocation of c-Rel was not ob-
viously affected after 1h BCR stimulation, c-Rel binding ac-
tivity was fractionally reduced by Nfkb1SSAA mutation (Fig. 4, 
C and D). However, Nfkb1SSAA mutation had a more pronounced 
effect on the second wave of c-Rel activation that results from 
prolonged BCR stimulation (Damdinsuren et al., 2010), de-
tected at 12 h (Fig. 4 D). Both p50 and RelA nuclear transloca-
tions and binding activities were reduced by Nfkb1SSAA mutation 
after 4-h CD40L stimulation. In contrast, CD40L-induced 
et al., 1991), were mixed at 4:1 ratio with BM cells from WT 
or Nfkb1SSAA/SSAA mice. These were then transferred into 
irradiated Rag1/ mice, producing chimeric mice in which 
all B cells had a WT (Nfkb1+/+) or Nfkb1SSAA/SSAA genotype, 
whereas 80% of the other hematopoietic cells had a WT geno-
type. After reconstitution for 8 wk, chimeric mice were then 
injected with NP27-CGG precipitated in alum or alum-only 
control. Nfkb1SSAA mutation totally blocked the production 
of serum anti-NP IgM and IgG1 at 7 and 14 d (Fig. 2 A), 
although the numbers of splenic B cells were equivalent be-
tween WT and Nfkb1SSAA/SSAA chimeric mice (Fig. 2 B, left). 
Nfkb1SSAA mutation also prevented the generation of anti–
NP-specific plasmablasts (Fig. 2 B, right) and anti–NP-specific 
GC B cells (Fig. 2 C). Furthermore, immunofluorescence 
analysis of spleen sections demonstrated the absence of GC 
structures in Nfkb1SSAA/SSAA chimeras after NP27-CGG-alum 
immunization (Fig. 2 D), which is consistent with a reduction 
in total GC B cell numbers (Fig. 2 C, left). Analysis of allotype-
marked mixed BM chimeras confirmed that the effect of 
Nfkb1SSAA mutation on generation of anti-NP–specific plas-
mablasts was B cell intrinsic (Fig. 2 E).
The results in this section demonstrated an essential role 
for IKK-induced proteolysis of NF-B1 p105 within FM 
B cells for their participation in TD antibody responses.
Nfkb1SSAA mutation reduces BCR activation of NF-B
Our earlier work demonstrated that blockade of IKK-induced 
p105 proteolysis by Nfkb1SSAA mutation can impair the acti-
vation of both TPL-2 and NF-B in macrophages (Yang 
et al., 2012). Therefore, the inhibitory effects of Nfkb1SSAA mu-
tation on TD antibody responses could have resulted from re-
duced TPL-2 and/or NF-B activation in B cells. To investigate 
whether TPL-2 had important B cell–intrinsic functions in 
TD antibody responses, mixed BM chimeras were generated 
in which B cells lacked expression of TPL-2 (Dumitru et al., 
2000). Immunization of these chimeric mice with NP27-CGG 
revealed that TPL-2–deficient B cells produced a TD anti-
body response equivalent to that of WT controls (Fig. 3). This 
Figure 3. TPL-2 is not required for a B cell 
antibody response to TD antigen. WT or 
Map3k8/ BM cells were mixed with MT/ 
BM cells in a 1:4 ratio, and transferred into 
sublethally irradiated Rag1/ mice. After 8 wk, 
chimeras were immunized with NP27-CGG alum 
or PBS alum controls. (A) Flow cytometric analy-
sis of total naive B cells (IgM+B220+). (B) a-NP 
IgM and IgG1 serum antibody levels were quan-
tified by ELISA (mean ± SEM), 14 d after  
NP27-CGG immunization. (C) Splenic a-NP IgG1+ 
plasmablasts (PB; B220loIgMloIgDCD138+) 7d 
after NP27-CGG immunization (mean absolute 
number ± SEM). (D) Splenic a-NP IgG1+ GC  
B cells 14 d after NP27-CGG immunization 
(mean absolute number ± SEM). All results are 
representative of two independent experiments 










Published September 15, 2014
2090 NF-B1 p105 regulation of TD antibody response | Jacque et al.
Furthermore, in vitro studies with purified splenic B cells from 
Rel-deficient mice have suggested that NF-B promotes the cell 
growth, proliferation and survival of mature B cells after BCR 
stimulation (Gerondakis and Siebenlist, 2010a; Kaileh and Sen, 
2012). As NF-B activation was impaired by Nfkb1SSAA muta-
tion, we next compared the growth, proliferation and survival of 
Nfkb1SSAA/SSAA FM B cells with WT cells. Nfkb1SSAA mutation 
did not affect FM B cell growth (Fig. 5 A), and only modestly 
decreased the fraction of FM B cells that divided following anti-
IgM stimulation (Fig. 5 B). However, Nfkb1SSAA mutation pre-
vented BCR ligation increasing FM B cell survival (Fig. 5 C). 
CD40-induced proliferation and survival were similar between 
Nfkb1SSAA/SSAA and WT FM B cells (Fig. 5, B and C). The sur-
vival defect of Nfkb1SSAA/SSAA FM B cells after BCR cross-
linking was rescued by co-stimulation with CD40L (Fig. 5 D).
nuclear translocations and NF-B binding activities of c-Rel, 
RelB, and NF-B2 p52 were similar between Nfkb1SSAA/SSAA 
and WT FM B cells. Thus, the major effects of Nfkb1SSAA mu-
tation in FM B cells were to reduce the early activation of 
canonical NF-B subunits p50 and RelA, after stimulation of 
either BCR or CD40, and the late activation of c-Rel after 
prolonged BCR cross-linking. p50, RelA and c-Rel each co-
immunoprecipitated with p105, suggesting that Nfkb1SSAA mu-
tation reduced activation of these Rel subunits, in part, by 
p105SSAA retention in the cytoplasm (Fig. 4 E).
Nfkb1SSAA mutation prevents BCR  
augmentation of FM B cell survival
Optimal TD antibody responses depend on the clonal expansion 
and survival of antigen-stimulated B cells (Oracki et al., 2010). 
Figure 4. Effects of Nfkb1SSAA mutation on NF-B activation in FM B cells. (A) Lysates of purified splenic FM B cells from WT or Nfkb1SSAA/SSAA 
mice were immunoblotted for the indicated proteins. (B) Purified splenic FM B cells from WT mice were stimulated with a-IgM or CD40L, and whole-cell 
extracts immunoblotted. (C) Purified splenic FM B cells were stimulated with a-IgM (1 h) or CD40L (4 h). Nuclear fractions were immunoblotted. 
(D) Nuclear fractions were prepared as in C, and NF-B binding of the indicated Rel subunits was determined by ELISA (mean ± SEM). To assay late acti-
vation of c-Rel, FM B cells were stimulated with anti-IgM for 12 h. (E) p105 was immunoprecipitated (IP) from lysates of purified splenic FM B cells. 
Associated Rel proteins were detected by immunoblotting. Pre-immune serum was used for control immunoprecipitations (CTL). All results are  
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mount an IgG1 antibody response to NP27-CGG, while the 
IgM anti-NP response was substantially reduced compared 
with WT Bcl-xl chimera controls (Fig. 6 B). The recovery of 
transplanted FM B cells from MD4 Nfkb1SSAA/SSAA mice, which 
express a transgenic BCR specific for HEL (hen egg lyso-
zyme; Goodnow et al., 1988), was increased by Bcl-xl expres-
sion (Fig. 6 C). However, MD4 Bcl-xl Nfkb1SSAA/SSAA B cells 
did not differentiate into plasmablasts or GC B cells after 
immunization with HEL-SRBC, in contrast to MD4 Bcl-xl 
Nfkb1+/+ control B cells under the same conditions (Fig. 6 C 
and Fig. S2). Thus, Nfkb1SSAA mutation did not block TD 
antibody responses solely by reducing BCR-induced FM 
B cell survival.
Nfkb1SSAA mutation does not block B cell migration  
to the follicle T cell zone or antigen presenting function
The antigen-specific interaction between B cells and helper 
T cells in secondary lymphoid organs is an essential step in TD 
humoral immune responses (Cyster, 2005). T cells provide a 
second signal via CD40 ligand, which promotes B cell sur-
vival and proliferation, and prevents B cell paralysis following 
BCR stimulation (Goodnow et al., 2010). Our observation 
that Nfkb1SSAA mutation did not affect CD40L induction of 
FM B cell proliferation or survival (Fig. 5, B and C), and that 
CD40 co-stimulation rescued the BCR-induced survival de-
fect of Nfkb1SSAA/SSAA FM B cells in vitro (Fig. 5 D) raised the 
possibility that these cells failed to receive a signal from CD4+ 
T cells after NP27-CGG immunization.
NF-B was previously shown to maintain the viability 
of BCR-activated B cells by inducing the expression of 
Bcl-xl and A1 (Bfl-1) genes (Grumont et al., 1999; Köntgen 
et al., 1995). Expression of Mcl-1, which is essential for sur-
vival of mature B cells (Hettmann et al., 2003) and plasma 
cells (Peperzak et al., 2013), may also be regulated by NF-B 
(Buggins et al., 2010). To gain further insight into how IKK-
induced p105 proteolysis regulates B cell survival, we deter-
mined the expression of these genes in purified FM B cells 
from Nfkb1SSAA/SSAA and WT FM mice. Nfkb1SSAA muta-
tion significantly reduced BCR up-regulation of Bcl-xl, A1, 
and Mcl-1 mRNAs (Fig. 5 E). CD40 induction of Bcl-xl and 
Mcl-1 mRNAs was also reduced in Nfkb1SSAA/SSAA FM B cells 
compared with WT. In contrast, CD40 up-regulation of A1 
mRNA was similar between genotypes, which may explain 
why CD40-induced FM B cell survival was not altered by 
Nfkb1SSAA mutation.
Together these results suggested that failure of the BCR 
to up-regulate Bcl-2 family proteins in Nfkb1SSAA/SSAA FM 
B cells increased apoptosis, and might explain the block in TD 
antibody responses caused by Nfkb1SSAA mutation. To inves-
tigate this hypothesis, we crossed Nfkb1SSAA/SSAA mice with a 
transgenic mouse strain that overexpresses Bcl-xl in the B cell 
lineage (Takahashi et al., 1999). In vitro experiments demon-
strated that Bcl-xl normalized Nfkb1SSAA/SSAA FM B cell sur-
vival after BCR stimulation (Fig. 6 A). Nevertheless, chimeric 
mice in which the B cell compartment was generated from 
the BM of Bcl-xl Nfkb1SSAA/SSAA mice were still unable to 
Figure 5. Effects of Nfkb1SSAA mutation on FM B cell survival and proliferation. (A) Flow cytometric analysis of cell growth (forward scatter) on 
purified FM B cells cultured in presence of a-IgM, for 24 h. Unstimulated WT FM B cells are represented in gray. (B) Purified splenic FM B cells plus a-IgM, 
CD40L, and IL-4 or control medium () were cultured for 68 h. The fraction of FM B cells that had divided was determined by flow cytometric analysis of 
CFSE dilution (mean ± SEM; triplicates). (C and D) Purified splenic FM B cells were cultured for 48 h with a-IgM, CD40L plus IL-4, a-IgM plus CD40L and 
IL-4, or control medium (-). The fraction of live FM B cells was determined by flow cytometric analysis of 7AAD staining (mean ± SEM; triplicates).  
(E) Triplicate cultures of purified splenic FM B cells were stimulated with a-IgM for 1 h or with CD40L for 4 h. Levels of specific mRNAs were determined 
by quantitative RT-PCR. Data are normalized to Hprt1 mRNA levels and represent mean fold change (±SEM) relative to unstimulated WT cells. All results 
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was impaired. A model system was used to assay this 
(Huntington et al., 2006), in which OVA was targeted to the 
BCR by treating Nfkb1SSAA/SSAA and WT FM B cells sequen-
tially with biotinylated anti-IgM and antibiotin OVA-FITC. 
Antigen-pulsed B cells were then co-cultured with CTV-labeled 
OTII CD4+ T cells, which recognize OVA-derived peptides 
presented on I-Ab class II molecules. Flow cytometric 
analysis of OTII CD4+ T cell proliferation indicated that 
Nfkb1SSAA/SSAA FM B cells were able to process and present 
OVA peptides in an active process requiring viable cells as 
efficiently as WT cells (Fig. 7 D). In accordance with these 
data, BCR up-regulation of CD86 and MHC class II was 
equivalent between Nfkb1SSAA/SSAA and WT FM B cells (un-
published data). The absence of a TD antibody response in 
Nfkb1SSAA/SSAA chimeric mice, therefore, did not result from a 
block in the ability of FM B cells to present antigen.
Nfkb1SSAA mutation blocks the differentiation  
of FM B cells to plasma cells
After antigen exposure and T cell help, proliferating B cells 
differentiate into either short-lived extrafollicular plasma cells 
or GC B cells, which subsequently generate plasma cells that 
secrete high-affinity antibody and persist for a lifetime. 
Although GC did not develop after NP27-CGG immuniza-
tion of Nfkb1SSAA/SSAA chimeric mice (Fig. 2 C), the lack of 
anti-NP IgM and IgG1 at 7d suggested that the inhibitory 
effect of Nfkb1SSAA mutation might precede GC formation. 
The complete lack of NP27-specific IgM plasma cells in 
Nfkb1SSAA/SSAA chimeric mice raised the possibility that 
After binding antigen, efficient FM B cell interaction 
with CD4+ T cells is facilitated by BCR up-regulation of 
CCR7, which induces FM B cell migration to the B cell 
zone-T cell zone boundary of the follicle in response to the 
T zone-expressed CCR7 ligand, CCL21 (Pereira et al., 2010). 
CCR7 is an NF-B–regulated gene (Krappmann et al., 2004), 
but Nfkb1SSAA mutation did not impair the up-regulation of 
CCR7 expression on FM B cells following BCR ligation 
(Fig. 7 A). Furthermore, anti-IgM-induced mRNA expres-
sion of Epstein-Barr virus-induced molecule 2 (EBI-2), an-
other NF-B–regulated gene (Glynne et al., 2000) encoding 
a cytokine which facilitates the initial uniform distribution of 
B cells along the B/T border (Gatto et al., 2009), was also 
unaffected by Nfkb1SSAA mutation (Fig. 7 B). Consistent with 
these data, anti-IgM-stimulated CD45.2+ Nfkb1SSAA/SSAA FM 
B cells migrated to the follicle-T cell zone border after trans-
fer into wild-type CD45.1+ recipients, similar to their WT 
counterparts (Fig. 7 C). These results suggest that a failure to 
co-localize with T cells did not explain the defective function 
of Nfkb1SSAA/SSAA B cells in TD antibody responses. However, 
we cannot exclude some contribution of the NF-B1 signaling 
pathway in this process, as in vitro stimulation before cell 
transfer may not completely replicate the in vivo environment.
For productive T cell-B cell cooperation in TD antibody 
responses, B cells must capture external antigens and present 
them as peptide fragments on MHC class II molecules to 
CD4+ T cells (Yuseff et al., 2013). It was therefore possible 
that while Nfkb1SSAA mutation did not inhibit T cell–B cell 
co-localization, the antigen presenting function of FM B cells 
Figure 6. Bcl-xl overexpression does not rescue the TD antibody response of Nfkb1SSAA/SSAA FM B cells. (A) The fraction of live FM B cells 
purified from mice of the indicated genotypes was determined as in Fig. 5 C (mean ± SEM). (B) Mixed radiation chimeras were made as in Fig. 2. LH 
graph show flow cytometric analysis of splenic B220+ IgM+ B cells. Central and RH graphs show anti-NP ELISAs of sera (mean ± SEM) 14 d after  
NP27-CGG immunization. Results are representative of three independent experiments (4–5 mice per genotype). (C) Mean percentages (±SEM) of trans-
ferred CD45.2+ cells (left) differentiating to plasmablasts (B220loIgMloIgDCD138+CD45.2+; middle) and GC B cells (B220+PNAhiGL7+ CD45.2+; right) in 
the spleens of CD45.1+ WT hosts after 6d immunization with SRBC-HEL or unconjugated SRBC. Results are representative of two independent experi-
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Nfkb1SSAA mutation might affect plasmablast differentia-
tion of FM B cells.
Plasma cell differentiation depends on high expression of 
the transcription factors BLIMP-1 (B lymphocyte-induced 
maturation protein 1) and IRF4 (interferon regulatory factor 4). 
The transcription of Prdm1 (encoding BLIMP-1) and Irf4 
genes is regulated by NF-B (Grumont and Gerondakis, 
2000; Saito et al., 2007; Morgan et al., 2009), although the 
role of NF-B activation in plasma cell differentiation has 
not been investigated. The failure to generate antigen-specific 
plasmablasts in Nfkb1SSAA/SSAA chimeric mice suggested that 
Nfkb1SSAA mutation might prevent antigen-stimulated FM 
B cells differentiating into plasmablasts by affecting the ex-
pression of these transcription factors. To initially investigate 
this, qRT-PCR was used to determine Prdm1 and Irf4 mRNA 
levels in cultured FM B cells. We found that Nfkb1SSAA muta-
tion significantly reduced the mRNA levels of both genes in-
duced by stimulation with anti-IgM (Fig. 8 A). LPS induction 
of Irf4 mRNA was also decreased in Nfkb1SSAA/SSAA FM 
B cells compared with WT controls, which correlated with a 
defect in LPS activation of NF-B (unpublished data). In 
accordance with these latter data, flow cytometric analyses 
demonstrated that Nfkb1SSAA mutation prevented FM B cells 
(from mice transgenic for Bcl-xl to maintain cell survival) 
from up-regulating IRF4 protein and differentiating into 
B220loCD138+ plasmablasts secreting IgM after stimulation 
with LPS plus IL-4 (Fig. 8, B and C). Nfkb1SSAA mutation also 
prevented LPS plus IL-4 induced switching to IgG1 (Fig. 8 D), 
consistent with the critical role of IRF4 in class switch re-
combination (Sciammas et al., 2006). Importantly, the in-
hibitory effect of Nfkb1SSAA/SSAA mutation on plasmablast 
differentiation was confirmed in vivo. Purified FM B cells 
from MD4 Bcl-xl Nfkb1SSAA/SSAA mice did not differentiate 
into plasmablasts after transfer to WT recipient mice and con-
comitant immunization with HEL-SRBC, which contrasted 
markedly with the MD4 Bcl-xl Nfkb1+/+ control B cells 
under the same conditions (Fig. 6 C and Fig. S2). This defect 
in MD4 Bcl-xl Nfkb1SSAA/SSAA B cells correlated with im-
paired up-regulation of IRF4 (Fig. 8 E and Fig. S3 A) and 
down-regulation of IgD (Fig. S3 A). Transient expression of 
Irf4 is essential for up-regulation of Bcl6 and generation of 
GC B cells (Ochiai et al., 2013). In line with this, Nfkb1SSAA 
mutation blocked antigen-induced up-regulation of BCL6 
(Fig. 8 F and Fig. S3 B) and the formation of GC B cells 
(Fig. 6 C and Fig. S2 B).
To determine whether the reduction of Irf4 and/or Prdm1 
mRNA levels caused by Nfkb1SSAA mutation was responsible for 
the block in plasma cell differentiation, WT and Nfkb1SSAA/SSAA 
FM B cells were transduced with recombinant retroviruses 
encoding BLIMP-1 or IRF4. Restoring IRF4 expression in-
creased the fraction of Nfkb1SSAA/SSAA FM B cells that differ-
entiated into plasmablasts sixfold after restimulation with LPS 
and IL-4 in vitro, whereas BLIMP-1 expression had little 
effect (Fig. 8 G). Furthermore, retroviral expression of IRF4 
in purified FM B cells from MD4 Bcl-xl Nfkb1SSAA/SSAA 
mice rescued antigen-induced generation of GC B cells after 
Figure 7. Nfkb1SSAA/SSAA B cells migrate normally to follicle  
T cell zone. (A) Flow cytometric analysis of CCR7 surface expression 
on purified FM B cells, cultured ± a-IgM for 6 h. Graphs represent 
CCR7 mean fluorescent intensity (±SEM) of live B cells (7AADB220+). 
(B) Triplicate cultures of purified splenic FM B cells cultured ± a-IgM for 1 h. 
Expression of Ebi-2 mRNAs was determined by quantitative RT-PCR. 
Data were normalized to Hprt1 mRNA levels and represent mean fold 
change (±SEM) relative to unstimulated WT cells. All results are repre-
sentative of at least two independent experiments done, with  
3 mice/genotype each. (C) Splenic distribution of WT and Nfkb1SSAA/SSAA 
CD45.2+ B cells, prestimulated in vitro for 1 h with a-IgM or control 
buffer (), 5.5 h after transfer in to CD45.1+ WT hosts. Transferred  
B cells were detected by staining for CD45.2 (green), whereas host  
B cells and T cells were stained with antibodies to IgD (red) and CD4 
(blue), respectively. Views are representative of at least two mice of 
each type. (D) Purified antigen-pulsed (Ag+) or not pulsed (Ag) B cells 
were co-culture with purified CTV-labeled OTII CD4+ T cells for 72 h. 
The fraction of OTII CD4+ that had divided was determined by flow 
cytometric analysis of CTV dilution (mean ± SEM; triplicates). All re-
sults are representative of at least two independent experiments done, 
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Figure 8. Nfkb1SSAA mutation impairs plasma cell differentiation. (A) Purified splenic FM B cells were cultured (triplicates) with a-IgM for 1 h 
or with LPS for 3 h. Expression of Irf4 and Prdm-1 mRNAs was determined by quantitative RT-PCR. Data were normalized to Hprt1 mRNA levels and 
represent mean fold change (±SEM) relative to unstimulated WT cells. All results are representative of at least three independent experiments (3 mice/
genotype each). (B) Histograms show intracellular IRF4 staining in live purified FM B cells cultured ± LPS and IL-4 (40 h). (C) FM B cells were stimu-
lated with LPS and IL-4 for 4 d. CD138+B220lo plasma cells among the live (7AAD) lymphocytes were quantified by flow cytometry. (middle) Mean 
percentages of plasma cells (±SEM). (right) IgM secretion as quantified by ELISA (mean ± SEM). (D) Purified FM B cells were stimulated with LPS and 
IL-4 for 3 d. Fractions of IgG1+ live B cells (B220+7AAD) were determined by flow cytometry (±SEM; E) Graphs show the mean percentages (±SEM) 
of transferred CD45.2+ cells up-regulating intracellular IRF4 expression in the spleens of CD45.1+ WT hosts after 6d immunization with SRBC-HEL or 
unconjugated SRBC. These results are representative of four independent experiments (n = 6 mice per condition). The gating strategies used are 
shown in Fig. S3 A. (F) Mean fluorescent intensities (MFI) of intracellular Bcl6 in transferred CD45.2+ B cells after 6-d immunization with SRBC-HEL or 
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Finally, to investigate the importance of p50 in the inhib-
itory effect of Nfkb1SSAA mutation on TD antibody responses, 
we generated mixed BM chimeras and then immunized with 
NP27-CGG. The titers of anti-NP IgM and IgG1 in the serum, 
as well as the number of anti-NP IgG1 plasma cells and GC 
B cells in the spleens of chimeras reconstituted with Nfkb1SSAA/ 
BM, were significantly reduced compared with Nfbk1+/ 
control chimeras (Fig. 9 G and not depicted). In contrast, no 
significant differences were detected between chimeras gen-
erated with Nfbk1+/ and Nfkb1SSAA/DCT BM cells. There-
fore, rescuing NF-B activation by increasing p50 levels 
with the Nfkb1DCT allele overcame the inhibitory effect of 
Nfkb1SSAA mutation on the FM B cell antibody response to 
a TD antigen.
DISCUSSION
Analyses of conditional knockout mouse strains lacking IKK2 
or NEMO expression in the B cell lineage have demonstrated 
that canonical NF-B activation is critical for mature B cell 
generation or homeostasis (Pasparakis et al., 2002; Li et al., 
2003). However, this has prevented using such mouse strains 
for investigation of the potential role for canonical NF-B 
activation in B cells for antibody production during an im-
mune response. In the present study, we used Nfkb1SSAA/SSAA 
mice, in which the development and homeostasis of periph-
eral FM B cells were normal, to investigate the role of NF-B 
activation in FM B cells in humoral immunity. Nfkb1SSAA mu-
tation selectively inhibits the IKK signaling pathway that reg-
ulates NF-B activation by inducing NF-B1 p105 proteolysis 
(Sriskantharajah et al., 2009). Our results demonstrate for the 
first time that IKK-induced p105 proteolysis is required for 
optimal BCR activation of NF-B in B cells, and that this is 
essential for generation of a TD antibody response, specifically 
regulating the survival of FM B cells and their differentiation 
to plasmablasts and GC B cells after BCR stimulation.
Nfkb1SSAA mutation reduced activation of p50 and RelA 
after both BCR and CD40 stimulation. Activation of c-Rel 
was also significantly reduced in Nfkb1SSAA/SSAA FM B cells 
compared with WT, particularly after prolonged BCR stimu-
lation. Immunoprecipitation and immunoblotting demon-
strated that p50, RelA, and c-Rel were able to interact with 
p105. The inhibitory effect of Nfkb1SSAA mutation on the ac-
tivation of these Rel subunits, therefore, probably resulted from 
their retention in the cytoplasm by p105SSAA. In addition, 
steady-state levels of p50 were reduced in Nfkb1SSAA/SSAA FM 
B cells compared with WT controls, suggesting that Nfkb1SSAA 
mutation reduced p105 processing to p50, similar to the situ-
ation we previously described in macrophages (Yang et al., 
transfer to WT recipient mice (Fig. 8 H and Fig. S4). Insuffi-
cient plasmablasts were generated in chimeric mice for quan-
titation. Together, these results suggested that the inhibitory 
effect of Nfkb1SSAA mutation on TD antibody responses re-
sulted partly from reduced BCR-mediated up-regulation of 
Irf4 mRNA, which blocked differentiation of FM B cells to 
plasmablasts and GC B cells.
Increasing p50 levels overcomes the inhibitory effect  
of Nfkb1SSAA mutation on TD B cell antibody responses
Our in vitro experiments indicated that a major effect of 
Nfkb1SSAA mutation with respect to NF-B was to reduce 
the steady-state levels and activation of NF-B1 p50 in FM 
B cells. To investigate the role of reduced p50 levels in the 
function of Nfkb1SSAA/SSAA FM B cells, Nfkb1SSAA/SSAA mice 
were crossed with Nfkb1DCT/DCT mice, which express elevated 
amounts of p50 compared with WT cells and no p105 (Ishikawa 
et al., 1998), as described previously (Yang et al., 2012). For 
comparison with these Nfkb1SSAA/DCT mice, Nfbk1+/ and 
Nfkb1SSAA/ strains were also generated. Nfkb1SSAA/DCT FM 
B cells expressed higher amounts of p50 compared with Nfkb1+/ 
cells, whereas p50 levels were very low in Nfkb1SSAA/ FM B 
cells (Fig. 9 A). The steady-state concentrations of p105SSAA 
were similar between Nfkb1SSAA/ and Nfkb1SSAA/DCT FM B 
cells. NF-B ELISAs revealed reduced BCR activation of 
p50, RelA, and c-Rel in Nfkb1SSAA/ FM B cells compared 
with Nfkb1+/ cells (Fig. 9 B). However, increasing p50 levels 
with the Nfkb1DCT allele normalized BCR activation of all 
three Rel subunits.
BCR-induced survival was reduced in Nfkb1SSAA/ FM 
B cells in comparison with Nfbk1+/ controls (Fig. 9 C), as ex-
pected. In contrast, survival of Nfkb1SSAA/DCT FM B cells after 
BCR cross-linking was similar to Nfbk1+/ controls. BCR-
induced proliferation was similar between the three genotypes 
(unpublished data), in line with the small inhibitory effect of 
homozygous Nfkb1SSAA mutation on anti-IgM–induced cell 
division (Fig. 5 B). Nfkb1SSAA mutation reduced both survival 
and proliferation of FM B cells after TLR4 stimulation, and 
these inhibitory effects were rescued by the Nfkb1DCT allele 
(Fig. 9 C and not depicted). The impairment by Nfkb1SSAA 
mutation of IRF4 up-regulation, differentiation to CD138+ 
B220lo plasmablasts and switching to IgG1 after LPS and IL-4 
stimulation of FM B cells were also overcome by the Nfkb1DCT 
allele (Fig. 9, D–F). These results showed that the reduced sur-
vival, plasmablast differentiation and class switch recombina-
tion of FM B cells in vitro caused by Nfkb1SSAA mutation were 
rescued by increasing p50 levels with the Nfkb1DCT allele, which 
normalized NF-B activation.
(G) FM B cells were transduced with recombinant retroviruses. The fraction of GFP+ cells differentiating to plasma cells (B220loIgDCD138+) after 
stimulation with LPS and IL-4 was quantified by flow cytometry (±SEM). Results are representative of three independent experiments (3 mice/ 
genotype each). (H) FM B cells were transduced with the indicated retroviruses (E.V., empty vector). The fraction of transferred GFP+ CD45.2+ cells 
differentiating to GC B cells (B220+PNAhiGL7+ CD45.2+) after 6-d immunization with SRBC-HEL or unconjugated SRBC are shown. Results are repre-
sentative of two independent experiments (n = 4–6 mice per condition). The gating strategies used are shown in Fig. S5. *, P < 0.05; **, P < 0.01;  
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Figure 9. Increasing p50 levels overcomes the inhibitory effect of Nfkb1SSAA mutation on FM B cell function. (A) Lysates of purified splenic FM 
B cells were immunoblotted. (B) Binding of the indicated Rel subunits to an NF-B oligonucleotide was determined by ELISA (mean ± SEM). (C) The frac-
tions of live FM B cells were determined as described in Fig. 5 C (mean ± SEM). (D) Intracellular IRF4 in live purified FM B cells ± LPS and IL-4 (40 h) was 
quantified by flow cytometry. (E) Plasma cell differentiation was monitored as in Fig. 8 C. (F) Purified FM B cells were stimulated with LPS and IL-4 for 3 d. 
The fractions of IgG1+ live B cells (B220+7AAD) were determined by flow cytometry (±SEM). (G) Mixed radiation chimeras were made as in Fig. 2. Naive B 
(B220+, IgM+) cells and aNP+ IgG1+ plasmablasts (PB) and GC B cells were quantified by flow cytometry (mean absolute number ± SEM) 7 and 14 d after 
NP27-CGG immunization, respectively. a-NP IgM and IgG1 serum antibody levels were quantified by ELISA (mean ± SEM) 14 d after NP27-CGG immu-
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CD19-Cre Irf4fl/fl mice have a substantially reduced GC 
response, and residual GCs form only with B cells in which 
the Irf4 allele has not been deleted (Ochiai et al., 2013). IRF4, 
therefore, plays an essential and B cell autonomous role in GC 
formation, regulating the expression of the key GC transcrip-
tion factor Bcl6 (Goodnow et al., 2010; Ochiai et al., 2013). 
Antigen-stimulated Nfkb1SSAA/SSAA FM B cells did not up-
regulate Bcl6 or differentiate into GC B cells during a TD 
immune response. NF-B signaling activity is very low in GC 
B cell centroblasts (Shaffer et al., 2001; Basso et al., 2004). 
However, IRF4 is required for the initiation, but not mainte-
nance of the GC state (Klein et al., 2006; Ochiai et al., 2013). 
This suggests that Nfkb1SSAA mutation may have prevented 
the initiation of GC formation by inhibition of NF-B– 
dependent transcriptional up-regulation of Irf4. Consistent 
with this hypothesis, retroviral expression of IRF4 signi-
ficantly increased antigen-induced differentiation of MD4 
Bcl-xl Nfkb1SSAA/SSAA B cells. The failure to induce IRF4 in 
Nfkb1SSAA/SSAA B cells was a feature of agonist of the BCR 
and TLR4, but not CD40 (unpublished data). As TLR signal-
ing is not required for antibody responses to antigens deliv-
ered in alum (Gavin et al., 2006), this suggests that the immune 
response defects detected were primarily caused by impaired 
BCR-mediated signaling.
In this study, we investigated the role of IKK-induced NF-
B1 p105 proteolysis in mature B cells, using Nfkb1SSAA/SSAA 
mice in which this IKK signaling pathway is blocked 
(Sriskantharajah et al., 2009). Nfkb1SSAA mutation prevented 
FM B cells from mounting an antibody response to a TD an-
tigen by selectively blocking BCR-induction of BCL-2 fam-
ily proteins and IRF4, which impaired FM B cell survival and 
antigen-induced differentiation of FM B cells to plasmablasts 
and GC B cells, respectively. Our study demonstrates that the 
regulation of NF-B activation in mature B cells by IKK-
induced NF-B1 p105 proteolysis is essential for TD humoral 
immune responses.
MATERIALS AND METHODS
Mouse strains. Mouse strains were bred in the specific pathogen–free ani-
mal facility of the National Institute for Medical Research (NIMR; London, 
UK). 7–12-wk-old mice were used for all experiments. Rag1/ (Mombaerts 
et al., 1992), MT/ (Kitamura et al., 1991), and HEL-specific BCR 
transgenic mice (MD4; Mason et al., 1992) and Nfkb1SSAA/SSAA (Sriskantharajah 
et al., 2009), Nfkb1/ (Sha et al., 1995), and Map3k8/ (Dumitru et al., 
2000) mouse strains have been previously described and were all fully back-
crossed on to a C57BL/6 background. Nfkb1+/, Nfkb1SSAA/- and Nfkb1SSAA/CT 
(Ishikawa et al., 1998) mice were generated by intercrossing Nfkb1SSAA/SSAA, 
Nfkb1CT/ CT, and Nfkb1/ strains. Nfkb1SSAA/SSAA.Bcl-xL and Nfkb1+/+.Bcl-xL 
mice experimental mice were generated by intercrossing Bcl-xL transgenic 
mice (Takahashi et al., 1999) with Nfkb1SSAA/SSAA and C57BL/6 mouse strains, 
respectively. These were subsequently intercrossed with MD4.Rag1/ mice 
to generate MD4.Rag1+/.Nfkb1SSAA/SSAA.Bcl-xL and MD4.Rag1+/.Nfkb1+/+. 
Bcl-xL mice.
This study was conducted following authorization by the UK Home 
Office, under relevant Project Licence authority.
BM chimeras and B cell adoptive transfer. BM cells were harvested 
from femora and tibiae of the indicated donor mice, and resuspended in 
ACK lysis buffer (155 mM NH4Cl, 10 mM KHCO3, 100 µM EDTA) to 
2012). The Nfkb1DCT allele overcame the inhibitory effect 
of Nfkb1SSAA mutation on BCR activation of p50, RelA, and 
c-Rel, presumably by increasing p50 expression to a degree 
that the concentration of p50 exceeded p105 (p105:p50 
[Nfkb1SSAA/DCT] = 0.63 ± 0.03; p105:p50 [Nfkb1SSAA/] = 
4.04 ± 0.3). Consequently, p105SSAA became saturated with 
p50 monomers and homodimers, with which it preferentially 
binds (Moorthy and Ghosh, 2003), and no longer able to 
block BCR activation of RelA and c-Rel monomers and 
p50/RelA and p50/c-Rel heterodimers. Remarkably, the 
Nfkb1DCT allele also normalized FM B cell survival and plas-
mablast differentiation in vitro, and TD antibody responses 
in vivo, demonstrating that the inhibitory effects of Nfkb1SSAA 
mutation on FM B cell function resulted from impaired 
NF-B activation.
Nfkb1SSAA mutation did not affect RelB and p52 NF-B–
binding activity in CD40L-stimulated cells, presumably because 
these subunits are predominantly associated with NF-B2 p100 
(Solan et al., 2002). Inability to inhibit activation of the alter-
native NF-B pathway probably explains why Nfkb1SSAA mu-
tation did not affect A1 mRNA up-regulation and the 
survival of FM B cells after CD40 stimulation, which activates 
both canonical and alternative NF-B signaling pathways 
(Rickert et al., 2011). CD40 co-stimulation overcame the 
BCR-induced survival defect of Nfkb1SSAA/SSAA FM B cells 
in vitro. However, although these cells could co-localize and 
presumably interact with CD40 on T cells in the spleen after 
BCR cross-linking, they still failed to mount an antibody re-
sponse to NP27-CGG. This suggests that defective survival 
alone did not block the TD antibody response of Nfkb1SSAA/SSAA 
FM B cells. In line with this, transgenic overexpression of 
Bcl-xl, which restored in vitro BCR-induced survival of 
Nfkb1SSAA/SSAA FM B cells to normal, did not rescue antibody 
responses to a TD antigen.
Nfkb1SSAA mutation blocked the late activation of c-Rel 
after BCR cross-linking with anti-IgM, and impaired BCR 
induction of Irf4 mRNA, a c-Rel–regulated gene (Grumont 
and Gerondakis, 2000). The up-regulation of IRF4 protein 
expression in MD4 B cells by HEL antigen in vivo was also 
prevented by Nfkb1SSAA mutation, confirming the physiologi-
cal significance of these findings. IRF4 is a critical transcrip-
tion factor for the induction of plasma cell differentiation and 
Ig class switch recombination (Sciammas et al., 2006; De Silva 
et al., 2012). Consistent with this, Nfkb1SSAA mutation reduced 
the ability of LPS plus IL-4 to induce IRF4 expression in FM 
B cells, impairing differentiation to IgM-secreting plasmablasts 
and switching to IgG1. The induction of plasmablast differen-
tiation of MD4 B cells in vivo by HEL was also prevented by 
Nfkb1SSAA mutation. In addition, retroviral expression of 
IRF4 rescued plasma cell differentiation of Nfkb1SSAA/SSAAv 
FM B cells stimulated with LPS and IL-4, confirming a func-
tional effect of reduced IRF4 in these cells. These experiments 
establish Irf4 as a physiologically important transcriptional tar-
get of the NF-B1 signaling pathway in B cell antibody re-
sponses, and demonstrate for the first time the critical role of 
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the manufacturer’s protocol. Intracellular IRF4 was detected using IRF4-PE 
(eBRG1), after cell permeabilization (Foxp3 Fixation/Permeabilization kit; 
eBioscience). Live cells (Live/dead Fixable Neat-IR Dead Cell Stain kit; 
Life Technologies) and extracellular markers were identified by prior stain-
ing of intact cells.
Stained cells were analyzed by flow cytometry on a CyAn ADP Ana-
lyzer (Beckman Coulter) or FACSCanto II Analyzer (BD). Data analyses 
were performed with FlowJo 887 software (Tree Star).
B cell isolation and in vitro culture. Splenic follicular B cells were iso-
lated by sequential hypotonic lysis of RBC and magnetic bead separation 
using a mixture of biotinylated anti-CD43 and anti-CD1d antibodies and 
Streptavidin-coupled Dynabeads (Life Technologies). Purity of the resulting 
FM B cell population (B220+CD23hiCD21lo) was >96% as assessed by flow 
cytometry. Cells were cultured at a density of 2 × 106 cells/ml in complete 
medium (DMEM plus 10% heat inactivated FCS [Lonza], 100 U/ml Peni-
cillin, 100 µg/ml Streptomycin, 100 µM nonessential amino acids, 100 mM 
Na-Pyruvate, and 50 µM 2-mercaptoethanol), and stimulated with anti-IgM 
(10 µg/ml; Jackson ImmunoResearch Laboratories), CD40L (0.5 µg/ml; 
R&D Systems), or LPS (1–10 µg/ml; Salmonella minnesota R595; Alexis Bio-
chemicals) ± IL-4 (20 ng/ml; PeproTech).
For in vitro survival assays, 3 × 105 B cells were cultured in a 96-well 
tissue-culture plate in complete medium (200 µl) with or without stimula-
tion (see above). Cells were harvested 2 d later, stained for a B cell marker 
(B220 or CD19) resuspended and 7-amino-actinomycin D (7-AAD; Sigma-
Aldrich). Cell division was monitored by flow cytometry after labeling of 
FM B cells with 2 µM CFSE (CellTrace; Invitrogen) in Dulbecco’s PBS 
(Invitrogen). The frequency of the precursor population triggered into cell 
division was determined using FlowJo V8.5 proliferation analysis software 
(Tree Star). To monitor the antigen-presenting function of FM B cells, 
OVA was targeted to the BCR by treating purified B cells sequentially 
with biotinylated anti-IgM (0.5 µg/ml; Jackson ImmunoResearch Laborato-
ries) and anti-biotin OVA-FITC (Miltenyi Biotec). Antigen-pulsed B cells 
(2 × 106/ml) were then co-cultured with Cell Trace Violet-labeled OTII 
CD4+ T cells (5 µM; Life Technologies; 1 × 106/ml) for 72 h. T cell activa-
tion was determined by estimating the ability of T cells to divide. To dem-
onstrate that OVA presentation was actively mediated, antigen-pulsed B cells 
were fixed in 3% paraformaldehyde before co-culture with T cells.
To monitor plasma cell differentiation, FM B cells (1.5 × 106/ml) were 
cultured with LPS (40 µg/ml) plus IL-4 (20 ng/ml) for 4 d. Plasma cells 
(B220loCD138+) were identified by flow cytometry. In vitro IgM production 
was analyzed by harvesting cells after 4-d culture with LPS and IL-4, and re-
plating washed live cells at 106 cells/ml in complete medium. Supernatants 
were collected after an additional 1-d culture, and analyzed by ELISA. The 
yields of Nfkb1SSAA/SSAA and WT FM B cells were similar after reculture.
Retroviral infection. pMSCV-IRES-GFP, pMSCV-IRF4-IRES-GFP, 
and pMSCV-Blimp-IRES-GFP plasmids (Kallies et al., 2007) were a gift 
from A. Kallies (The Walter and Eliza Hall Institute of Medical Research, 
Parkville, Victoria, Australia). Retroviruses were prepared as previously de-
scribed using Plat-E packaging cells (Robinson et al., 2007). FM B cells were 
cultured for 24 h with CD40L and IL-4 before retroviral infection. To ana-
lyze the effect of ectopic IRF4 expression on GC B cell formation, purified 
MD4.Rag1+/.Nfkb1SSAA/SSAA.Bcl-xL and MD4.Rag1+/.Nfkb1+/+.Bcl-xL FM 
B cells were transduced twice with retrovirus, prior to cotransfer with 0.5 
to 1.109 HEL-conjugated or control sheep red blood cells (SRBC) into 
CD45.1+ C57BL/6 hosts by intravenous injection. Splenic B cells were ana-
lyzed by flow cytometry after 6 d.
Protein analyses. For immunoblots of total lysates, FM B cells (3 × 106 
cells per point) were lysed RIPA buffer (50 mM Tris, pH 7.5, 150 mM 
NaCl, 2 mM EDTA, 50 mM NaF, 2 mM Na4P2O7, 5 mM dithiothreitol, 
1 mM Na3VO4, protease inhibitors [Roche], 0.5% deoxycholate, 1% Triton 
X-100, and 0.1% SDS). After centrifugation, lysates (20–25 µg) were mixed with 
an equal volume of 2x SDS-PAGE sample buffer. For immunoprecipitation, 
lyse red blood cells. Cells (4–5 × 106 per mouse) were then transferred by 
intravenous injection into sublethally irradiated Rag1/ mice (500 rads; Cs 
source). For competition experiments, BM cell suspensions from CD45.1+ 
C57BL/6 were mixed with either Nfkb1SSAA/SSAA or wild-type Nfkb1+/+ 
CD45.2+ BM cells, at a 1:1 ratio. For mixed BM chimeras, sublethally irradi-
ated Rag1/ mice were reconstituted with Nfkb1SSAA/SSAA or wild-type 
Nfkb1+/+ BM cells mixed at 1:4 ratio with MT/ BM cells. Chimeric 
mice were immunized 8 wk after reconstitution.
To analyze B cell positioning in the spleen after BCR stimulation, 8–10 × 106 
splenic purified B cells from either Nfkb1SSAA/SSAA or wild-type mice were 
cultured in vitro with or without anti-IgM (10 µg/ml; Jackson Immuno-
Research Laboratories) for 1 h (Pereira et al., 2009). Cells were then trans-
ferred into CD45.1+ C57BL/6 hosts by intravenous injection, and spleens 
removed 5.5 h later for immunofluorescence analysis.
To monitor plasma cell differentiation and GC B cell formation in vivo, 
8–10 × 106 splenic purified B cells from MD4.Rag1+/.Nfkb1SSAA/SSAA.BcL-xL 
and MD4.Rag1+/.Nfkb1+/+.Bcl-xL were cotransferred with 0.5–1.109  
HEL-conjugated or control sheep red blood cells into CD45.1+ C57BL/6 
hosts by intravenous injection (Reif et al., 2002; Kelly et al., 2011). 6 d after 
transfer, recipient mice were culled and spleens were removed for flow cy-
tometric analysis.
Assay of antibody responses. For TD antibody responses, mixed BM 
chimeras were immunized i.p. with 50 µg NP27-CGG in PBS (Biosearch 
Technologies) precipitated in alum (Imject; Thermo Fisher Scientific; 3:1 
ratio). Alum mixed with PBS was used as a control. The production of 
NP-specific and total immunoglobulins (IgM and IgG1) was monitored by 
ELISA, using 96-well Maxisorp ELISA plates pretreated with 50 µl/well of 
5 µg/ml NP14.-BSA (Biosearch Technologies). Antibody isotypes and sub-
classes were detected with horseradish peroxidase–conjugated mouse IgM 
and subclass IgG-specific antibodies (Southern Biotech).
Histological analyses. Cryosections (7–10 µM) of spleen were prepared, 
dried, and fixed with acetone before immunofluorescent analysis (Turner 
et al., 1997). GC B cells were stained using GL7-FITC mAb (Ly77, BD), 
revealed with rabbit anti-FITC (Alexa Fluor 488 Signal-Amplification kit; 
Invitrogen), IgD-PE (11-26c; eBioscience), and B220-Alexa Fluor 647 (RA3-
6B2, BD). For B cell migration assays, CD45.2-FITC (104, eBioscience), 
CD4-Alexa Fluor 647 (ABD Serotec), and IgD-PE (11-26c; eBioscience) 
were used to identify transferred B cells. Spleen sections were analyzed by im-
munofluorescence microscopy using either a Leica confocal microscope TSP-
SP2 (Leica) or a DeltaVision RT Imaging System (Applied Precision Inc.).
Flow cytometry. Single-cell suspensions were generated from peripheral 
lymph nodes, spleen, BM, or peritoneal wash via gentle homogenization 
through nylon mesh filters (70 µM; BD). Erythrocytes in BMs and spleens 
were lysed with ACK lysis buffer before staining, and cell concentrations 
were determined using a Casy Counter (Scharfe Instrument Systems). CD1d-
PE and CD1d-bio (clone 1B1); CD21-FITC (eBio8D9); CD23-PE (B3B4); 
B220-FITC, B220-PE, B220-APC, and B220-eFluor450 (RA3-6B2); 
CD93-APC (AA4.1); IgM-PECy7 (II/41); IgD-FITC, IgD-eFluor450, 
IgD-PE, and IgD-bio (11–26); Ly5.1-FITC, and Ly5.1-APC (A20); Ly5.2-
FITC, and Ly5.2-APC-eFluor780 (104), CD43-bio (eBioR2/60), IgG1-
APC (X56), Gr1-bio (RB6-8C5), CD11b-Bio (M1/70); CD11c-Bio 
(N418); CD5-PE (53–7.3); CD19-FITC (MB19-1); TCRb-FITC (H57-
597); and CCL19-Fc fusion protein (plus anti–human Fc-PE secondary 
to stain CCR7) were obtained from eBioscience. CD4-PerCP (RM4-5), 
B220-PcP (RA3-6B2), and CD8-PerCP (53–6.7) were purchased from Bio-
Legend; CD2-PE (RM2-5), CD9-bio (KMC8), CD21-PE (7G6), Streptavi-
din-PerCP (554064), CD138-PE (281–2), and GL7-FITC (Ly77) were 
obtained from BD; PNA-Bio (FL-1075) was purchased from Vector Labo-
ratories; and CD19-APC (RM705) and CD23-APC (MCD2305) were pur-
chased from Life Technologies. For thymus-dependent (TD) antibody 
response assays, NP27-BSA (Biosearch Technologies) was labeled with the 
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cells (5 × 107 per point) were lysed in IP buffer (10 mM Hepes, 
pH 7.6, 1 mM EGTA, 10 mM KCl, 1 mM dithiothreitol, 20 mM NaF, 1 mM 
Na4P2O7, protease inhibitors, and 0.6% Nonidet-P40). Immunoprecipitations 
(150 µg of protein extract) were performed as previously described (Kabouridis 
et al., 1997).
To analyze nuclear translocation of Rel subunits, washed cells were 
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1.5 mM MgCl2, 1 mM DTT, 20 mM NaF, 1 mM Na-pyrophosphate, pro-
tease inhibitors, and 0.2% NP-40). After 2 min, nuclei were pelleted by cen-
trifugation, washed twice in lysis buffer, and nuclear proteins extracted with 
RIPA buffer. Rel proteins in nuclear extracts (20 µg) were quantified by 
immunoblotting and laser densitometry, normalizing to SAM68 content.
The p105C antibody to the p105 C terminus, used for p105 immuno-
precipitation, has been described previously (Salmerón et al., 2001). p50 
antibody was obtained from (Delta Biolabs) and phospho S933 p105 antibody 
from Cell Signaling Technology. Antibodies to other Rel family proteins, 
SAM68 and IBa, were purchased from Santa Cruz Biotechnology, Inc. 
Tubulin was detected with TAT-1 a-tubulin mAb (provided by K. Gull, 
University of Oxford, Oxford, England, UK) and used as loading control 
protein on immunoblots of total cell lysates.
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ELISA kit (TransAm NF-B family kit; Active Motif). To increase sensitiv-
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Real-time quantitative PCR. RNA from stimulated and unstimulated FM 
B cells (5 × 106/ml) was isolated using the RNeasy kit, and contaminating 
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facturer’s instructions and DNase treated (Roche). cDNA was produced using 
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mined by real time PCR using a Perkin Elmer ABI Prism 7000 Sequence 
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with the TaqMan Gene Expression Master Mix (Applied Biosystems). Target 
gene mRNA levels were normalized against Hprt mRNA levels.
Statistical analysis. All data analyses were performed using GraphPad soft-
ware (GraphPad Software Inc.). In vitro data were compared using Student’s 
t test (two tailed and unpaired test). For in vivo experiments, all statistical 
comparisons were performed using the nonparametric two-tailed Mann-
Whitney test. Statistically significant differences are indicated as follows: 
*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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